查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726176

美國介入性腫瘤學市場規模、佔有率、趨勢分析報告：按程序、程序、應用、最終用途、細分預測，2025-2030

U.S. Interventional Oncology Market Size, Share & Trends Analysis Report By Technique (Ablation Therapies, Embolization Therapies), By Procedure (Tumor Ablation, Tumor Biopsy), By Application, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

美國介入性腫瘤學市場趨勢

預計 2024 年美國介入性腫瘤市場規模將達到 9.984 億美元，2025 年至 2030 年複合年成長率為 8.17%。

由於癌症發生率的上升、微創手術技術的進步、介入性腫瘤學領域的投資增加以及老齡人口的增加，市場正在成長。

美國癌症盛行率的上升是推動市場成長的一個主要因素。根據美國癌症協會統計，美國新增癌症病例2,041,910例。在美國，預計 2025 年將出現 2,041,910 例新發癌症病例，同年預計將有 618,120 人死於癌症。化療和放射線治療等傳統治療方法通常具有明顯的副作用，因此射頻消融和微波消融等微創替代療法越來越受歡迎。這些手術可局部破壞腫瘤，同時最大程度地減少對周圍組織的損傷，從而改善患者的治療效果並推動對介入性腫瘤學解決方案的需求。

介入性腫瘤學技術的持續進步正在提高這些手術的有效性和採用率。在這個市場營運的公司正專注於創新，將先進的產品推向市場，從而改善患者的治療效果。例如，2023 年 9 月，Profound Medical 的 TULSA-PRO Thermal Boost 模組獲得了美國FDA 的 510(k) 許可，該模組可以暫時提高前列腺特定區域的消融溫度。熱增強功能改善了 88% 前列腺癌病例的治療效果，提高了治療效果和工作流程效率。這些進步改善了臨床結果並增加了介入性腫瘤學對醫療保健提供者的吸引力。

在美國，公共和私營部門對介入腫瘤學的投資不斷增加，正在加速市場擴張。我們的開發、研發和創業投資投資支持推進精準腫瘤學的創新治療方法的開發，並確保介入技術融入主流癌症治療。例如，2024年12月，介入放射學會（SIR）基金會向四個研究計劃頒發了150萬美元的津貼。一項是開發新型肝細胞癌（HCC）模型的研究，另一項是利用基因亞型對HCC進行精準引導介入的研究。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國介入腫瘤學市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 介入性腫瘤學市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析

第4章美國介入性腫瘤學市場（按程序、估計和趨勢分析）

  • 細分儀表板
  • 美國介入性腫瘤學市場程序變化分析
  • 2018-2030年美國介入性腫瘤學市場規模及趨勢分析（依手術方式）
  • 消融治療
    • 射頻消融術（RFA）
    • 微波消融（MWA）
    • 冷凍療法
    • 雷射消熔
    • 不可逆電穿孔（IRE）
  • 栓塞治療
    • 經動脈化療栓塞術（TACE）
    • 經動脈放射栓塞術（TARE）
  • 切片檢查技術
    • 芯針切片
    • 細針抽吸（FNA）
  • 標靶治療輸送系統
    • 藥物釋放型珠
    • 放射栓塞術
    • 藥物釋放型支架
    • 可注射水凝膠和奈米顆粒
    • 其他標靶治療系統
  • 影像導引手術
    • 超音波引導
    • 電腦斷層掃描指導
    • MRI導
    • 透視引導

第5章美國介入性腫瘤學市場（按程序、估計和趨勢分析）

  • 細分儀表板
  • 美國介入性腫瘤學市場程序變化分析
  • 美國介入性腫瘤學市場規模及趨勢分析（依程序，2018-2030）
  • 腫瘤消融
  • 腫瘤切片檢查
  • 血管介入
  • 安寧療護

第6章美國介入性腫瘤材料市場的應用、估計與趨勢分析

  • 細分儀表板
  • 美國介入性腫瘤學市場使用變化分析
  • 美國介入性腫瘤學市場規模及應用趨勢分析（2018-2030）
  • 肝癌
  • 肺癌
  • 腎癌
  • 攝護腺癌
  • 乳癌
  • 其他癌症

第7章美國介入腫瘤學市場最終用途、預測與趨勢分析

  • 細分儀表板
  • 美國介入腫瘤學市場的最終用途差異分析
  • 2018-2030年美國介入性腫瘤學市場規模及趨勢分析（依最終用途）
  • 醫院
  • 專科診所
  • 其他

第8章 競爭態勢

  • 公司/競爭對手分類
  • 戰略地圖
  • 2024年企業市場分析
  • 公司簡介/上市公司
    • Medtronic
    • Boston Scientific Corporation
    • Johnson & Johnson（Ethicon）
    • Cook Medical
    • AngioDynamics Inc.
    • Stryker
    • Terumo Corporation
    • Siemens Healthineers（Varian）
    • Teleflex Incorporated
    • Profound Medical
Product Code: GVR-4-68040-550-1

U.S. Interventional Oncology Market Trends:

The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.

The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.

Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.

The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.

U.S. Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:

  • Technique Outlook (Revenue, USD Million, 2018 - 2030)
  • Ablation Therapies
    • Radiofrequency Ablation (RFA)
    • Microwave Ablation (MWA)
    • Cryoablation
    • Laser Ablation
    • Irreversible Electroporation (IRE)
  • Embolization Therapies
    • Transarterial Chemoembolization (TACE)
    • Transarterial Radioembolization (TARE)
  • Biopsy Techniques
    • Core Needle Biopsy
    • Fine Needle Aspiration (FNA)
  • Targeted Therapy Delivery Systems
    • Drug-Eluting Beads
    • Radioembolization
    • Drug-Eluting Stents
    • Injectable Hydrogels and Nanoparticles
    • Other Targeted Therapy Systems
  • Image-Guided Procedures
    • Ultrasound Guidance
    • CT Scan Guidance
    • MRI Guidance
    • Fluoroscopy Guidance
  • Procedure Outlook (Revenue, USD Million, 2018 - 2030)
  • Tumor Ablation
  • Tumor Biopsy
  • Vascular Interventions
  • Palliative Care
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Specialty Clinics
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Technique Segment
    • 1.2.2. Procedure Segment
    • 1.2.3. Application Segment
    • 1.2.4. End-use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. U.S. Interventional Oncology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
      • 3.2.1.3. Growing geriatric population
      • 3.2.1.4. Increasing investments in the field of interventional oncology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with interventional oncology
      • 3.2.2.2. Requirement of highly skilled professionals
  • 3.3. Interventional Oncology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Interventional Oncology Market: Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Interventional Oncology Market Technique Movement Analysis
  • 4.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
  • 4.4. Ablation Therapies
    • 4.4.1. Ablation Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Radiofrequency Ablation (RFA)
      • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Microwave Ablation (MWA)
      • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Cryoablation
      • 4.4.4.1. Cryoablation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Laser Ablation
      • 4.4.5.1. Laser Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Irreversible Electroporation (IRE)
      • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Embolization Therapies
    • 4.5.1. Embolization Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.2. Transarterial Chemoembolization (TACE)
      • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.3. Transarterial Radioembolization (TARE)
      • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Biopsy Techniques
    • 4.6.1. Biopsy Techniques market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.2. Core Needle Biopsy
      • 4.6.2.1. Core Needle Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.3. Fine Needle Aspiration (FNA)
      • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Targeted Therapy Delivery Systems
    • 4.7.1. Drug Delivery Systems market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.2. Drug-Eluting Beads
      • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.3. Radioembolization
      • 4.7.3.1. Radioembolization market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.4. Drug-Eluting Stents
      • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.5. Injectable Hydrogels and Nanoparticles
      • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.6. Other Targeted Therapy Systems
      • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Image-Guided Procedures
    • 4.8.1. Image-Guided Procedures market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.2. Ultrasound Guidance
      • 4.8.2.1. Ultrasound Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.3. CT Scan Guidance
      • 4.8.3.1. CT Scan Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.4. MRI Guidance
      • 4.8.4.1. MRI Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.5. Fluoroscopy Guidance
      • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Oncology Market: Procedures Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Interventional Oncology Market Procedures Movement Analysis
  • 5.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Procedures, 2018 to 2030 (USD Million)
  • 5.4. Tumor Ablation
    • 5.4.1. Tumor Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Tumor Biopsy
    • 5.5.1. Tumor Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Vascular Interventions
    • 5.6.1. Vascular Interventions market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Palliative Care
    • 5.7.1. Palliative Care market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Interventional Oncology Market Applications Movement Analysis
  • 6.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Applications, 2018 to 2030 (USD Million)
  • 6.4. Liver Cancer
    • 6.4.1. Liver Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Lung Cancer
    • 6.5.1. Lung Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Kidney Cancer
    • 6.6.1. Kidney Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Prostate Cancer
    • 6.7.1. Prostate Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Breast Cancer
    • 6.8.1. Breast Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. Other Cancer
    • 6.9.1. Other Cancer market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. U.S. Interventional Oncology Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Interventional Oncology Market End Use Movement Analysis
  • 7.3. U.S. Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Specialty Clinics
    • 7.5.1. Specialty Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Medtronic
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson (Ethicon)
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Cook Medical
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. AngioDynamics Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Stryker
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Terumo Corporation
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Siemens Healthineers (Varian)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Teleflex Incorporated
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Profound Medical
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. interventional oncology market by modality, 2018 - 2030 (USD Million)
  • Table 4 U.S. interventional oncology market by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S interventional oncology market by mobility, 2018 - 2030 (USD Million)
  • Table 6 U.S interventional oncology market by end use, 2018 - 2030 (USD Million)
  • Table 7 Participant's overview
  • Table 8 Financial performance
  • Table 9 Key companies undergoing expansions
  • Table 10 Key companies undergoing acquisitions
  • Table 11 Key companies undergoing collaborations
  • Table 12 Key companies launching new products
  • Table 13 Key companies undergoing partnerships
  • Table 14 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 U.S. interventional oncology market: Market outlook
  • Fig. 5 U.S. interventional oncology market: Segment outlook
  • Fig. 6 U.S. interventional oncology market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 U.S. interventional oncology market driver impact
  • Fig. 9 U.S. interventional oncology market restraint impact
  • Fig. 10 U.S. interventional oncology market: Technique outlook and key takeaways
  • Fig. 11 U.S. interventional oncology market: Technique movement analysis
  • Fig. 12 Ablation therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Microwave Ablation (MWA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Cryoablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Laser Ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Irreversible Electroporation (IRE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Embolization therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Transarterial Chemoembolization (TACE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Biopsy rechniques market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Targeted therapy delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Drug-eluting beads market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Radioembolization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Drug-eluting stents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Other targeted therapy systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Image-guided procedures market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 ultrasound guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 CT scan guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 MRI guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Fluoroscopy Guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. interventional oncology market: Procedures outlook and key takeaways
  • Fig. 36 U.S. interventional oncology market: Procedures movement analysis
  • Fig. 37 Tumor ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Tumor biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Vascular interventions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Palliative care market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. interventional oncology market: Applications outlook and key takeaways
  • Fig. 42 U.S. interventional oncology market: Applications movement analysis
  • Fig. 43 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Other cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. interventional oncology market: End-use outlook and key takeaways
  • Fig. 50 U.S. interventional oncology market: End-use movement analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Specialty clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Heat map analysis
  • Fig. 56 Market participant categorization
  • Fig. 57 U.S. interventional oncology market share analysis, 2024
  • Fig. 58 Strategy framework